Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR tyrosine kinase inhibitor (TKI) from the anilinoquinazoline class of TKIs, developed by AstraZeneca Pharmaceuticals. Gefitinib selectively inhibits EGFR-stimulated tumor cell growth and blocks EGFR autophosphorylation in tumor cells by competitive inhibition of ATP binding to kinase domain of EGFR (Wakeling et al. 2002, Yun et al. 2007).
Yun, CH, Boggon, TJ, Li, Y, Woo, MS, Greulich, H, Meyerson, M, Eck, MJ
Wakeling, AE, Guy, SP, Woodburn, JR, Ashton, SE, Curry, BJ, Barker, AJ, Gibson, KH
© 2021 Reactome